Investigational drug · Phase 3
QL1206
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Postmenopausal Women With Osteoporosis at High Risk of Fracture.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "QL1206"
First trial start
2025
Jun 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QL1206", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postmenopausal Women With Osteoporosis at High Risk of Fracture
Approved drugs for the same conditions: Osteoporosis · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "QL1206" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid TumorsPivotal-lookingStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT04550949 · 700 participants (planned) · Start Apr 26, 2019 · Primary completion Mar 1, 2021
Drug: QL1206; Xgeva · For: Bone Metastases
Sites: Beijing, China; Guangzhou, China
- A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
Fresenius Kabi SwissBioSim GmbHIndustry
NCT04934072 · 553 participants · Start Jun 16, 2021 · Primary completion Aug 7, 2023
Drug: FKS518; US-licensed Prolia (Amgen) · For: Postmenopausal Osteoporosis
Sites: Sofia, Bulgaria; Haskovo, Bulgaria; Pleven, Bulgaria · 76 sites in all
- Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture RiskPivotal-lookingStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT04128163 · 440 participants (planned) · Start Jun 5, 2019 · Primary completion Aug 31, 2021
Drug: QL1206; Placebos · For: Postmenopausal Osteoporosis
Sites: Shanghai, China
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®Pivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07062978 · 278 participants (planned) · Start Jun 27, 2025 · Primary completion Jan 2027
Drug: QL1206; Prolia® · For: Postmenopausal Women With Osteoporosis at High Risk of Fracture
Sites: Guizhou, China
- A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced XgevaPivotal-lookingCompleted
mAbxience Research S.L.Industry
NCT05299073 · 257 participants · Start Mar 1, 2022 · Primary completion Mar 18, 2023
Drug: MB09; US-sourced Xgeva and 1 more · For: Healthy Volunteers
Sites: Józefów, Poland
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy AdultsPivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT03651947 · 168 participants · Start Aug 20, 2018 · Primary completion Nov 17, 2018
Drug: QL1206; Xgeva® · For: Healthy People
Sites: Changchun, China
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy AdultsPivotal-lookingStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT04213105 · 144 participants (planned) · Start Oct 31, 2019 · Primary completion Oct 31, 2020
Drug: QL1206; Prolia® · For: Healthy People
Sites: Changchun, China
Children's Oncology GroupResearch network
NCT02470091 · 56 participants · Start Nov 21, 2015 · Primary completion Dec 31, 2019
Drug: Denosumab · For: Metastatic Osteosarcoma; Recurrent Osteosarcoma; Refractory Osteosarcoma and 3 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 141 sites in all
National Cancer Institute (NCI)NIH
NCT03382574 · 2 participants · Start Mar 14, 2019 · Primary completion Oct 22, 2021
Drug: Denosumab · For: Ovarian Carcinoma
Sites: Boston, Massachusetts; New York, New York; Houston, Texas · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.
Liu Y, Zhang R, Wang X, et al. · Chin J Cancer Res 2025
- Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.
Li H, Huang Y, Chen Z, et al. · BioDrugs 2023
- A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
Zhang H, Gu JM, Chao AJ, et al. · Acta Pharmacol Sin 2023
- A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
Zhang H, Wu M, Zhu X, et al. · Front Pharmacol 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.